ATLANTA (GenomeWeb) – When researchers from Progenetica-Hermes Pardini Institute in Brazil screened a dozen patients using a next-generation sequencing-based gene panel test they developed, they uncovered a number of variants of unknown significance (VUS), one of the investigators said at the American Association for Clinical Chemistry annual meeting here yesterday.

Giovana Torrezan and her Progenetica colleagues screened a dozen women lacking BRCA1 or BRCA2 mutations for other breast cancer-linked mutations to find that eight of them harbored VUS.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.